SCHEMBL2384560

SCHEMBL2384560

O=C(Nc1cccc(C(F)(F)F)c1)N1CCN(c2nsnc2OCc2ccncc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 4/20 0.53
▸ LMNA P02545 3/20 0.51
▸ MAPT P10636 3/20 0.51
▸ KIT P10721 1/20 0.51
▸ EPHB4 P54760 1/20 0.49
▸ HTT P42858 2/20 0.48
▸ GOT1 P17174 1/20 0.47
▸ FAAH O00519 1/20 0.46
▸ F10 P00742 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ FGFR4 P22455 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ GPR142 Q7Z601 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384936 0.97 TRPV1 (0.50) TRPV1LMNAMAPTKITEPHB4
SCHEMBL2382772 0.93 TRPV1 (0.49) TRPV1KITHSD17B10
SCHEMBL2385592 0.90 TRPV1 (0.55) TRPV1LMNAMAPTKITEPHB4
SCHEMBL2386175 0.90 TRPV1 (0.47) TRPV1MAPTKITKDM4E
SCHEMBL2385717 0.87 TRPV1 (0.52) TRPV1LMNAMAPTKITEPHB4
SCHEMBL2385551 0.87 TRPV1 (0.51) TRPV1LMNAMAPTFAAHF10
SCHEMBL2384350 0.86 F10 (0.63) LMNAMAPTHTTF10KDM4E
SCHEMBL2384709 0.86 TRPV1 (0.53) TRPV1KITEPHB4F10
SCHEMBL12250883 0.86 TRPV1 (0.53) TRPV1KITEPHB4F10
SCHEMBL2383664 0.86 TRPV1 (0.53) TRPV1KITEPHB4F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR TRPV1 4108/4885LMNA 2968/4885MAPT 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback